Literature DB >> 9264362

Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system.

R S Bresalier1, P S Yan, J C Byrd, R Lotan, A Raz.   

Abstract

BACKGROUND: The 31-kilodalton beta-galactoside-binding protein galectin-3 has been associated with cellular transformation and metastasis. Because neural tissues contain large amounts of glycoconjugates, and endogenous carbohydrate-binding proteins have been described in the human brain, the authors examined the expression of galectin-3 in human brain tumors and metastases to the central nervous system.
METHODS: Brain tumors were categorized by the World Health Organization system and galectin-3 expression by immunoperoxidase staining using a quantitative staining score.
RESULTS: Glioblastomas (Grade 4 astrocytomas) all stained strongly for galectin-3, whereas low grade astrocytomas (Grade 2) did not express the endogenous lectin. Anaplastic astrocytomas (Grade 3) exhibited intermediate expression. The staining score was significantly associated with tumor grade (P < 0.001). Normal brain tissue and benign tumors did not express galectin-3, whereas metastases to the brain were all positive for galectin-3 expression. Metastases expressed significantly more galectin-3 than the primary tumors from which they were derived (P = 0.003).
CONCLUSIONS: Galectin-3 expression correlates with the malignant potential of tumors in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264362

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  36 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Pediatric glioblastoma cells inhibit neurogenesis and promote astrogenesis, phenotypic transformation and migration of human neural progenitor cells within cocultures.

Authors:  Kurt Farrell; Gautam Mahajan; Parthasarathy Srinivasan; Moo-Yeal Lee; Chandrasekhar R Kothapalli
Journal:  Exp Cell Res       Date:  2017-11-10       Impact factor: 3.905

3.  Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis.

Authors:  B K Moon; Y J Lee; P Battle; J M Jessup; A Raz; H R Kim
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

4.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

5.  Regulation of prostate cancer progression by galectin-3.

Authors:  Yi Wang; Pratima Nangia-Makker; Larry Tait; Vitaly Balan; Victor Hogan; Kenneth J Pienta; Avraham Raz
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

Review 6.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

7.  SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells.

Authors:  Heather M McClung; Stacey L Thomas; Pamela Osenkowski; Marta Toth; Priya Menon; Avraham Raz; Rafael Fridman; Sandra A Rempel
Journal:  Neurosci Lett       Date:  2007-04-21       Impact factor: 3.046

Review 8.  Glycosylation in bladder cancer.

Authors:  Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

Review 9.  Galectin-1: a bifunctional regulator of cellular proliferation.

Authors:  Ken Scott; Cristina Weinberg
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 10.  Galectins and gliomas.

Authors:  Marie Le Mercier; Shannon Fortin; Véronique Mathieu; Robert Kiss; Florence Lefranc
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.